Search the Newsreel

Should I Buy GUTS (Fractyl Health, Inc. Common Stock) | AI Analysis, Technical & News Insights

Fractyl Health, Inc. - Common Stock (Nasdaq:GUTS) Stock Quote

This article provides a stock quote for Fractyl Health, Inc. (Nasdaq: GUTS), detailing its current price, daily range, volume, and performance metrics. It also includes recent news headlines and press releases related to the company's financial results, clinical trial updates, and investor events. Key …

Q3 EPS Estimates for Fractyl Health Raised by HC Wainwright

HC Wainwright has increased its Q3 2026 EPS forecast for Fractyl Health (NASDAQ: GUTS) to a loss of $0.13 per share from a previously projected loss of $0.14, maintaining a Buy rating and an $8 price target. This revision follows Fractyl Health reporting a …

Fractyl Health at Canaccord conference: betting on post-glp-1 care

Fractyl Health presented at Canaccord Genuity's 46th Annual Growth Conference, outlining its focus on developing durable metabolic treatments for obesity and type 2 diabetes, particularly for post-GLP-1 weight maintenance. The company highlighted promising clinical data for its lead program, Revita, which is now in …

Analysts Set Expectations for Fractyl Health FY2028 Earnings

Fractyl Says Revita Procedure Kept Off 80% of GLP-1 Weight Loss in One-Year Data

Fractyl Health reported that its Revita endoscopic procedure helped patients maintain over 80% of GLP-1-induced weight loss one year after discontinuing the medications, significantly outperforming a sham group. The company expects to submit for FDA De Novo marketing clearance in late Q4 2026 and …

BofA Securities Maintains Fractyl Health(GUTS.US) With Buy Rating, Maintains Target Price $2

BofA Securities has reiterated its Buy rating for Fractyl Health (GUTS.US) and maintained a target price of $2. This continued positive outlook suggests the firm sees potential upside or stability in Fractyl Health's stock.

Fractyl Health Reports Second Quarter 2026 Financial Results and Business Updates

Fractyl Health, a clinical-stage metabolic therapeutics company, announced its Q2 2026 financial results and provided business updates. The company reported promising one-year data from its Revita procedure for weight maintenance post-GLP-1 discontinuation, with plans for an FDA De Novo submission in late Q4 2026. …

Fractyl Health Q2 Earnings Call Highlights

Fractyl Health announced that its Revita endoscopic procedure demonstrated durable weight-maintenance results one year after patients ceased GLP-1 therapy. The company reaffirmed plans to release pivotal trial data in early Q4 2026 and aims for a potential FDA De Novo submission later that year, …

Fractyl Health, Inc. reports results for the quarter ended June 30 - Earnings Summary

Fractyl Health, Inc. has released its earnings summary for the quarter that concluded on June 30. The article mentions that the full report is available through a subscription to Reuters and other news sources on TradingView.

Fractyl Health (NASDAQ:GUTS) Announces Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Fractyl Health (NASDAQ:GUTS) reported its quarterly earnings, missing analysts' consensus estimates by $0.02 with an EPS of ($0.16). The stock traded down $0.02 to $0.68, bringing its market capitalization to approximately $107 million. Despite the earnings miss, analyst sentiment remains a "Moderate Buy" with …

Fractyl Health (GUTS) Projected to Release Quarterly Earnings on Tuesday

Fractyl Health (GUTS) is expected to release its Q2 2026 earnings after market close on Tuesday, August 11th, with analysts forecasting a loss of $0.15 per share. The company's shares are currently trading near $0.70, significantly below their 52-week high, despite strong liquidity and …

Fractyl Health (GUTS.US) will release its earnings report after market close on August 10.

Fractyl Health (GUTS.US) is scheduled to release its earnings report after the market closes on August 10. Investors will be looking forward to the financial results from the company.

Fractyl Health to Report Second Quarter 2026 Financial Results and Provide Business Updates on August 10, 2026

Fractyl Health, Inc. (Nasdaq: GUTS) announced it will report its second-quarter 2026 financial results and provide business updates on Monday, August 10, 2026, at 4:30 p.m. ET. A live webcast of the conference call will be accessible on the company's investor relations website. Fractyl …

Fractyl Health Q2 Results: Earnings and updates on Aug 10

Fractyl Health Inc. is set to release its Q2 2026 financial results on August 10, 2026, including updates on its metabolic therapeutics pipeline. The company will provide insights into the development of Revita, a procedural therapy for post-GLP-1 weight maintenance, and Rejuva, an AAV-based …

Fractyl Health to report Q2 results, host conference call

Fractyl Health (NASDAQ: GUTS) has announced it will release its second-quarter 2026 financial results and host a business update conference call on August 10, 2026, at 4:30 p.m. ET. A live webcast will be available on the company's investor relations website, with a replay …

Enterprise value to EBITDA forward of Fractyl Health, Inc. – NASDAQ:GUTS

The article discusses the enterprise value to EBITDA (forward) of Fractyl Health, Inc., traded on NASDAQ under the symbol GUTS. It appears to be a financial data snippet from TradingView, indicating that the market for this stock is currently closed with no recent trades. …

Fractyl Health Inc (GUTS) Institutional Confidence

Fractyl Health Inc (GUTS) has an institutional shareholding score of 7.00, placing it 80th out of 386 in the Biotechnology & Medical Research industry. The institutional shareholding proportion increased by 17.40% quarter-over-quarter to 79.56%. Lee Ainslie is the largest institutional shareholder, holding 2.12M shares, …

Fractyl Health Inc (GUTS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article on Fractyl Health Inc (GUTS) states that relevant data regarding its revenue breakdown by business segment and region have not yet been disclosed by the company. It provides current stock information, including a market cap of $124.05 million and a recent stock …

Price to earnings forward of Fractyl Health, Inc. – NASDAQ:GUTS

This page from TradingView provides financial information for Fractyl Health, Inc. (NASDAQ:GUTS), specifically focusing on its price-to-earnings forward metric. The content indicates that the market is closed, and no trades have occurred for the stock. It appears to be a stub or placeholder page …

Fractyl Health Inc (GUTS) Cash Flow

This article provides a detailed quarterly cash flow statement for Fractyl Health Inc (GUTS), covering operating, investing, and financing activities from FY2020Q3 to FY2026Q1. It includes financial figures for net income, operating gains/losses, changes in working capital, capital expenditures, and various financing flows. The …

Fractyl Health Inc (GUTS) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Fractyl Health Inc (GUTS), listing major institutional holders and their proportional ownership. It provides data on top shareholders, breakdown by shareholder types (e.g., Hedge Fund, Venture Capital), and changes in institutional holdings over recent quarters. The report …

Fractyl Health Market Sentiment

The article provides an overview of market sentiment for Fractyl Health (GUTS), indicating an analyst consensus of "Buy" with a significant upside potential in price targets. It details recent analyst actions, including initiations, upgrades, downgrades, and maintained ratings, alongside information on short interest and …

GUTS|Fractyl Health Inc|Price:0.773|Chg%:+0.016

Fractyl Health Inc. (GUTS) is a metabolic therapeutics company focused on treating obesity and type 2 diabetes with its Revita and Rejuva platforms. The stock is currently priced at $0.773, up 2.15%, and is considered fairly valued with high growth potential and strong fundamentals. …

Enterprise value to revenue forward of Fractyl Health, Inc. – NASDAQ:GUTS

This article provides a financial data point for Fractyl Health, Inc. (NASDAQ: GUTS), specifically its enterprise value to revenue forward. It is presented within the context of TradingView's financial analysis tools, indicating this value as of a particular period with corresponding change metrics.

Fractyl Health to Participate in Upcoming Investor Events

Fractyl Health, a clinical-stage metabolic therapeutics company, announced its CEO, Harith Rajagopalan, M.D., Ph.D., will participate in several investor conferences in late July and August 2026. These events include the BTIG Virtual Biotechnology Conference, Needham & Company MedTech & Diagnostics 1x1 Conference, and the …

Fractyl Health CEO to present at key biotech investor conferences in July and August 2026

Fractyl Health, a clinical-stage company focusing on obesity and type 2 diabetes treatments, announced that its CEO, Harith Rajagopalan, will present at several investor conferences between late July and mid-August 2026. These appearances will include one-on-one meetings and a fireside chat at events such …

Fractyl Health CEO to Join Meetings and Aug. 12 Fireside Chat

Fractyl Health (Nasdaq: GUTS) CEO and Co-Founder Harith Rajagopalan, M.D., Ph.D., will participate in three upcoming investor conferences in July and August 2026, including one-on-one meetings and a fireside chat. These events include the BTIG Virtual Biotechnology Conference, the Needham & Company MedTech & …

Fractyl Health (GUTS) Morgan Stanley 22nd Annual Global Healthcare Conference summary

This article summarizes Fractyl Health's presentation at the Morgan Stanley 22nd Annual Global Healthcare Conference. It highlights the company's Revita procedure, an outpatient endoscopic treatment designed to address the root causes of obesity and diabetes for durable weight and glycemic control, especially after GLP-1 …

Fractyl Health (GUTS) AGM 2026 Summary

This article provides a summary of Fractyl Health's (GUTS) 2026 Annual General Meeting (AGM) held on June 10, 2026. Key agenda items included introductions of board and executive members, updates from board committees, and shareholder proposals for the election of three Class II directors …

Price to sales forward of Fractyl Health, Inc. – NASDAQ:GUTS

This article provides financial information for Fractyl Health, Inc. (NASDAQ: GUTS), specifically focusing on its forward price-to-sales ratio. It appears to be a stub or data-only page from TradingView, offering an overview of the company's financials without detailed analytical content in the current snippet.

Craig-Hallum Maintains Fractyl Health(GUTS.US) With Buy Rating, Maintains Target Price $4

Craig-Hallum has maintained its Buy rating on Fractyl Health (GUTS.US) and kept its target price at $4. This indicates a positive outlook from the firm regarding the company's stock performance.

Fractyl Health Helps Maintain Weight After Stopping Popular Obesity Drugs, Stock Soars

Fractyl Health's investigational Revita DMR System demonstrated its potential to help patients maintain weight loss after discontinuing GLP-1 treatments, according to one-year results from its REMAIN-1 study. The system significantly reduced weight regain by approximately 40% compared to a sham procedure, with even greater …